haNK: Clinical Trials

10 trials of haNK, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 withdrawn, 1 terminated. 10 Phase 1, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Withdrawn 9, Terminated 1
Phase 210Withdrawn 9, Terminated 1

Follow haNK: new trials by email Literature Review of haNK trials Research Report on haNK

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011 - Colorectal Cancer Metastatic, mCRC
Phase 1 / Phase 2TerminatedImmunityBio, Inc.22018-09-282024-12-11
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Aldoxorubicin Hydrochloride, ALT-803, ETBX-051 - Chordoma, Unresectable Malignant Neoplasm
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2018-08-312025-02-21
QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC
avelumab, bevacizumab, capecitabine - Colorectal Cancer
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2018-08-012025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
avelumab, Bevacizumab, Capecitabine - Non-small Cell Lung Cancer
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2018-02-012025-02-21
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
avelumab, bevacizumab, capecitabine - Triple Negative Breast Cancer
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Avelumab, Bevacizumab, Capecitabine - Melanoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-21
QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
Avelumab, Bevacizumab, Capecitabine - Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
avelumab, bevacizumab, capecitabine - Non Hodgkin Lymphoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-24
QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy
Avelumab, Bevacizumab, Capecitabine - Merkel Cell Carcinoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-21
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
avelumab, bevacizumab, capecitabine - Urothelial Carcinoma
Phase 1 / Phase 2WithdrawnImmunityBio, Inc.2017-12-012025-02-21

Conditions studied

Colorectal Neoplasms (2)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Transitional Cell (1)  ·  Chordoma (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Melanoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

ImmunityBio, Inc. (10)

Countries

United States (2)